Department of Neuro Oncology
Impact Points
Publications
Top Journals
Top Newcomers
Publications (428)
-
Article: Chapter 13 Autophagy Pathways in Glioblastoma
Methods in Enzymology. 453:273-286. -
Article: Atypical spasmus nutans as an initial sign of thalamic neoplasm.
Pediatric Neurology 2(6):375-6. · 1.52 Impact Factor -
Article: Convenient preparation of 4-(tetrazol-5-yl)-phenylalanine for use in Fmoc-based solid-phase peptide synthesis
Tetrahedron Letters 41(34):6555-6558. · 2.68 Impact Factor -
Article: Stereospecific synthesis of 4-carboxyphenylalanine and derivatives for use in Fmoc-based solid-phase peptide synthesis
Tetrahedron Letters 37(37):6661-6664. · 2.68 Impact Factor -
Article: Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
The Cancer Journal 14(5):279-85. · 3.26 Impact Factor -
Article: Narcotics and cancer pain control.
CA A Cancer Journal for Clinicians 38(6):322-6. · 101.78 Impact Factor -
Article: Influence of acidic residues on substrate specificity of oncogene products pp60v-src and p56lck in vitro.
Anticancer research 12(1):123-7. · 1.73 Impact Factor -
Article: New frontiers in therapy of malignant gliomas.
Forum (Genoa, Italy) 8(3):261-9. -
Article: Treatment of respiratory dyskinesia with olanzapine.
Psychosomatics 40(3):257-9. · 2.12 Impact Factor -
Article: Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling.
Oncology Reports 6(2):393-401. · 1.84 Impact Factor -
Article: Terminally ill cancer patients. Their most important concerns.
Cancer Practice 5(3):147-54. -
Article: Influence of solid support, solvent and coupling reagent on the head-to-tail cyclization of resin-bound peptides.
Peptide research 7(4):195-206. -
Article: Cyclooxygenase-2 inhibitors in glioma therapy.
American Journal of Therapeutics 11(2):141-3. · 1.49 Impact Factor -
Article: Cytogenetic and molecular abnormalities in astrocytic gliomas (Review).
Oncology Reports 7(2):401-12. · 1.84 Impact Factor -
Article: Advances in molecular therapies in patients with brain tumors.
Cancer control: journal of the Moffitt Cancer Center 10(2):125-37. -
Article: Chemotherapy and cognition: effects, potential mechanisms, and management.
American Journal of Therapeutics 13(4):362-9. · 1.49 Impact Factor -
Article: Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.
Journal of Neuro-Oncology 02/1987; 5(4):323-30. · 3.21 Impact Factor -
Article: Expression of an altered epidermal growth factor receptor by human glioblastoma cells.
Cancer Research 11/1988; 48(19):5433-9. · 7.86 Impact Factor -
Article: In vitro chemosensitivity testing and its clinical application in human gliomas.
Neurosurgical Review 02/1989; 12(3):197-203. · 2.04 Impact Factor -
Article: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells.
Cancer Research 03/1989; 49(4):1014-9. · 7.86 Impact Factor -
Article: Altered expression and distribution of heparan sulfate proteoglycans in human gliomas.
Cancer Research 05/1989; 49(8):2096-103. · 7.86 Impact Factor -
Article: Pain management in a drug-oriented society.
Cancer 07/1989; 63(11 Suppl):2383-6. · 4.77 Impact Factor -
Article: Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Journal of Neuro-Oncology 10/1989; 7(3):237-40. · 3.21 Impact Factor -
Article: The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen.
Journal of Neuro-Oncology 12/1989; 7(4):329-38. · 3.21 Impact Factor -
Article: Direct sequencing analysis of transmembrane region of human Neu gene by polymerase chain reaction.
Molecular Carcinogenesis 02/1990; 3(4):198-201. · 3.16 Impact Factor -
Article: Differential amplification of the TGF-alpha gene in human gliomas.
Cancer communications 02/1990; 2(6):201-5. -
Article: Peripheral neuropathy in cancer patients: incidence, features, and pathophysiology.
Oncology (Williston Park, N.Y.) 02/1990; 4(1):57-62 concl. · 1.03 Impact Factor -
Article: Peripheral neuropathy in cancer patients: clinical types, etiology, and presentation. Part 2.
Oncology (Williston Park, N.Y.) 03/1990; 4(2):85-9. · 1.03 Impact Factor -
Article: Inhibition of epidermal growth factor receptor activity by retinoic acid in glioma cells.
Journal of Cellular Biochemistry 03/1990; 42(2):83-94. · 2.87 Impact Factor -
Article: Neurologic complications of polycythemia and their impact on therapy.
Oncology (Williston Park, N.Y.) 04/1990; 4(3):59-64; discussion 64-6. · 1.03 Impact Factor -
Article: Modification of a commercially available method of extracting plasmid DNA.
BioTechniques 05/1990; 8(4):386. · 2.67 Impact Factor -
Article: Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment.
Oncology (Williston Park, N.Y.) 08/1990; 4(7):115-22; discussion 122, 126-7, 130. · 1.03 Impact Factor -
Article: Codon 72 polymorphism of the TP53 gene.
Nucleic Acids Research 09/1990; 18(16):4961. · 8.03 Impact Factor -
Article: A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.
Journal of Neuro-Oncology 09/1990; 9(1):29-34. · 3.21 Impact Factor -
Article: Chemotherapy for malignant brain tumors.
Current Opinion in Oncology 09/1990; 2(4):673-8. · 4.10 Impact Factor -
Article: Growth regulatory activities of endothelial extracellular matrix: mediation by transforming growth factor-beta.
Experimental Cell Research 10/1990; 190(1):127-32. · 3.58 Impact Factor -
Article: Leptomeningeal carcinomatosis.
American Journal of Clinical Oncology 01/1991; 13(6):536-40. · 2.01 Impact Factor -
Article: Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction.
Molecular Carcinogenesis 02/1991; 4(1):10-3. · 3.16 Impact Factor -
Article: Persistent neurotoxicity of systemically administered interferon-alpha.
Neurology 06/1991; 41(5):672-6. · 8.31 Impact Factor -
Article: Intravenous carboplatin for recurrent malignant glioma: a phase II study.
Journal of Clinical Oncology 06/1991; 9(5):860-4. · 18.37 Impact Factor -
Article: Pathways of oncogenesis in primary brain tumors.
Current Opinion in Oncology 07/1991; 3(3):476-84. · 4.10 Impact Factor -
Article: Inhibition of adenylate cyclase by tetraplatin.
Anti-Cancer Drugs 07/1991; 2(3):267-8. · 2.41 Impact Factor -
Article: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease.
Cancer 08/1991; 68(1):88-92. · 4.77 Impact Factor -
Article: Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.
Oncogene 10/1991; 6(9):1555-9. · 6.37 Impact Factor -
Article: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study.
Journal of Clinical Oncology 12/1991; 9(11):1945-9. · 18.37 Impact Factor -
Article: Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen-section mRNA.
Molecular Carcinogenesis 02/1992; 6(2):83-7. · 3.16 Impact Factor -
Article: An assay for acidic peptide substrates of protein kinases.
Analytical Biochemistry 03/1992; 200(2):347-51. · 3.00 Impact Factor -
Article: Cognitive functioning in cancer patients: effect of previous treatment.
Neurology 03/1992; 42(2):434-6. · 8.31 Impact Factor -
Article: The intractable pain treatment act of Texas.
Texas medicine 03/1992; 88(2):70-2. -
Article: Analgesic activity of anticancer agent suramin.
Anti-Cancer Drugs 05/1992; 3(2):91-4. · 2.41 Impact Factor
2,082.51
Total Impact Points
428
Publications
4.87
Avg. Impact Points
857
Authors
5.07
Avg. Authors Per Publ.